Medicare Advantage Prior Authorization for Medical Devices: Navigating the 2026 Rules
A comprehensive guide to Medicare Advantage prior authorization for medical devices. Learn about CMS-0057-F timelines, CY2026 rules, denial rates, and appeal strategies.
Medicare Advantage (MA) plans—private health insurance plans that contract with the Centers for Medicare & Medicaid Services (CMS) to deliver Medicare Part A and Part B benefits—have officially become the dominant model for Medicare delivery. Covering more than half of all eligible Medicare beneficiaries, MA plans represent the primary commercial target for most medical device manufacturers. However, securing a Food and Drug Administration (FDA) clearance or approval and obtaining a valid billing code is no longer enough to guarantee patient access or commercial adoption.
For medical device commercialization teams, the true gatekeeper of market access is utilization management, and specifically, the prior authorization (PA) process. Unlike traditional fee-for-service (FFS) Medicare, where coverage is determined retrospectively after a service is provided (unless the item falls under specific FFS prior authorization programs), Medicare Advantage plans rely heavily on prospective prior authorization to control utilization and costs.
In this comprehensive guide, we dissect the mechanics of Medicare Advantage prior authorization, examine the latest quantitative data on denial and appeal rates, analyze the major CMS regulatory overhauls taking effect in 2026, contrast MA plan practices against traditional Medicare, and present a practical playbook for medical device manufacturers to survive the prior authorization gantlet.
Scenario Question: Our Class II/III medical device has FDA clearance and an active HCPCS or C-code, but Medicare Advantage plans are repeatedly requiring prior authorization and denying or delaying our customer claims. What is happening within these plans, and how can we design our commercialization strategy to navigate it?
Direct Answer: While Medicare Advantage plans are legally required to cover the same basic services and technologies as traditional Medicare, they are permitted to apply utilization management tools like prior authorization. In 2026, 99% of all Medicare Advantage enrollees are in plans that require prior authorization for at least some services. In 2024, MA plans made nearly 53 million prior authorization determinations, issuing full or partial denials for approximately 4.1 million requests (a 7.7% denial rate). Crucially, while 80.7% of denials were overturned upon appeal, only 11.5% of denied requests were ever appealed.
To navigate this landscape, manufacturers must adapt to the CMS Interoperability and Prior Authorization Final Rule (CMS-0057-F)—which shortens standard prior authorization decision timelines from 14 to 7 calendar days starting January 1, 2026—and understand the CY2026 MA Final Rule's inpatient "approved-admission hold" and clarified appeal rights. Note one important caveat: the CY2026 rule's proposed mandate to make internal coverage criteria publicly available was deferred for future rulemaking and is not yet in force. Manufacturers must build robust clinical dossiers, embed documentation checklists in physician ordering workflows, engage proactively with payers on their internal coverage criteria, and establish dedicated reimbursement support programs to help providers execute the appeals process.
1. What Medicare Advantage Prior Authorization Means for Device Coverage
Prior authorization is a clinical review process where a healthcare provider must obtain approval from a health plan before performing a procedure, prescribing a drug, or supplying a medical device. If the provider fails to obtain authorization prior to delivering the service, the plan will deny the claim, leaving the provider or the patient with the financial burden.
Historically, traditional Medicare has rarely used prospective prior authorization, relying instead on post-payment audits, National Coverage Determinations (NCDs), and Local Coverage Determinations (LCDs) to manage coverage and payment. Medicare Advantage plans, however, operate under a capitated payment model where they receive a flat monthly fee per enrollee from CMS. This structure creates a strong financial incentive for plans to manage utilization.
Under federal regulations, Medicare Advantage plans must cover all services covered under Medicare Part A and Part B. Under 42 CFR § 422.101, an MA plan cannot deny coverage for a medical device or procedure if there is an active NCD or LCD that mandates coverage. However, plans are permitted to use prior authorization to verify that:
- The patient meets the specific clinical criteria outlined in the NCD or LCD.
- The device or procedure is medically necessary for the individual patient's clinical situation.
- The service is being delivered in the most appropriate, cost-effective clinical setting (e.g., outpatient clinic versus inpatient hospital).
This distinction is where many medical device manufacturers stumble. Having an active NCD or LCD that says "Medicare covers this device" does not mean an MA plan will pay for it automatically. The plan will use the prior authorization process as a screening mechanism, frequently applying its own clinical guidelines or third-party guidelines (such as InterQual or MCG) to determine whether the medical necessity threshold has been met. If you are still establishing that upstream coverage position, our guide to Medicare NCD versus LCD coverage determinations for devices covers how those determinations are built; this article picks up at the plan-level utilization management layer that sits on top of them.
For a new medical device, prior authorization represents the single biggest hurdle to early adoption. Even if a hospital value analysis committee approves a device for use, physicians will quickly stop ordering it if their billing departments spend hours fighting prior authorization denials or if the hospital is forced to write off the cost of the procedure.
2. Which Device-Related Service Categories Trigger Prior Authorization Most in MA
Prior authorization is not applied uniformly across all medical services. According to data analyzed by the Kaiser Family Foundation (KFF), the vast majority of Medicare Advantage enrollees are in plans that require prior authorization for high-cost, high-variability services.
Share of MA Enrollees in Plans Requiring Prior Authorization, 2026
Source: KFF, "Medicare Advantage in 2026"
+-------------------------------------------------------------+
| Any service (at least one) | 99% |
+-------------------------------------------------------------+
| Inpatient hospital stays (acute) | 97% |
| Skilled Nursing Facility (SNF) stays | 95% |
| Part B Drugs | 94% |
| Inpatient hospital stays (psychiatric) | 93% |
| Home Health Care Services | 90% |
| Preventive Services | 6% |
+-------------------------------------------------------------+
For medical device manufacturers, the primary exposure points for prior authorization fall into several distinct buckets:
A. Inpatient and Outpatient Surgical Procedures
High-cost implantable devices—such as spinal cord stimulators, deep brain stimulators, artificial joints, transcatheter heart valves (TAVR), and cardiac rhythm management devices—are almost universally subject to prior authorization. The PA review focuses not just on the device itself, but on whether the patient meets the clinical indications for the surgical procedure.
B. Durable Medical Equipment, Prosthetics, Orthotics, and Supplies (DMEPOS)
Traditional Medicare has its own specific DMEPOS prior authorization lists (which we analyze in our companion guide on DMEPOS prior authorization), but Medicare Advantage plans frequently go much further. Plans often require prior authorization for Class II and Class III DME items that are exempt from PA in traditional Medicare, such as continuous glucose monitors (CGMs), high-end respiratory equipment (non-invasive ventilators), advanced wound care products (like single-use negative pressure wound therapy), and active support surfaces.
C. Outpatient Diagnostics and Imaging
Advanced diagnostic devices, particularly computed tomography (CT) scanners, magnetic resonance imaging (MRI) systems, and positron emission tomography (PET) systems, are heavily managed. Prior authorization for these scans is usually outsourced to Radiology Benefit Managers (RBMs) who apply strict algorithmic criteria before approving the scan. For manufacturers of diagnostic systems, this clinical gatekeeping directly limits scan volumes, influencing hospital purchasing decisions and system utilization rates.
D. Post-Acute and Home Health Care Devices
Devices used during transition of care, such as compression therapy systems, specialized hospital beds, and patient monitors, are subject to the home health and post-acute prior authorization rules of MA plans. As plans seek to minimize hospital length of stay, securing prompt authorization for discharge-dependent devices is critical to avoiding discharge delays.
3. The 2024-2026 CMS Prior Authorization Rules (CMS-0057-F) and the 7-Day Standard
In response to growing pressure from providers, patients, and Congress, CMS finalized a landmark rule in January 2024: the CMS Interoperability and Prior Authorization Final Rule (CMS-0057-F). This regulation introduces major changes to how Medicare Advantage plans, state Medicaid agencies, and federal marketplace plans must administer prior authorization.
The most critical changes, which are fully effective January 1, 2026, include the following:
A. Shortened Decision Timelines
Prior to 2026, Medicare Advantage plans had up to 14 calendar days to issue a decision on a standard prior authorization request. For patients waiting for surgical implants, diagnostic scans, or therapeutic equipment, this two-week delay was a major barrier to care.
Beginning January 1, 2026, the standard decision timeline is cut in half:
- Standard Requests: Plans must issue a decision within 7 calendar days of receiving the request.
- Expedited Requests: The timeline remains at 72 hours for cases where a standard delay could seriously jeopardize the patient’s life, health, or ability to regain maximum function.
Prior Authorization Decision Timelines (Effective Jan 1, 2026)
+------------------------------------+--------------------------+
| Request Type | CMS Mandated Timeline |
+------------------------------------+--------------------------+
| Standard Prior Authorization | 7 Calendar Days |
| Expedited Prior Authorization | 72 Hours |
+------------------------------------+--------------------------+
B. Mandated Reason for Denials
Under 42 CFR § 422.122(a), beginning January 1, 2026, when an MA organization denies a prior authorization request within the timeframes at §§ 422.568(b)(1) and 422.572(a)(1), the response to the provider must include a specific reason for the denial, regardless of the method used to communicate it — portal, fax, email, mail, or phone. Generic statements like "does not meet medical necessity" no longer satisfy the requirement on their own. This sits alongside the pre-existing notice-content requirements at § 422.568(e), which the new rule supplements rather than replaces.
Two limits are worth knowing before you build a workflow around this. First, the requirement excludes prior authorization for drugs as defined at § 422.119(b)(1)(v), so Part B drug denials are outside its scope. Second, CMS declined to prescribe standardized denial-reason codes, leaving plans latitude in how granular "specific" is in practice — expect meaningful variation between plans in the first cycles, and treat a vague reason as itself a procedural argument rather than assuming the rule guarantees a usable one.
C. Electronic Prior Authorization (ePA) and FHIR APIs
To address the administrative burden of faxing clinical records and filling out portal forms, CMS-0057-F requires MA plans to build and maintain a Prior Authorization API based on the HL7 FHIR (Fast Healthcare Interoperability Resources) standard.
- This API allows a provider's Electronic Health Record (EHR) system to query the MA plan's system directly to determine if prior authorization is required for a specific HCPCS code.
- It identifies the specific documentation requirements for that code.
- It supports the electronic submission of the prior authorization request directly from the EHR.
While the API requirement must be operational by 2027, many plans are rolling out pilot systems in 2026. For device manufacturers, designing digital clinical decision support tools that integrate with provider EHRs and supply the necessary clinical data to these FHIR APIs will be a competitive necessity.
4. Denial Rates, Appeal Overturn Rates, and What the OIG/KFF Data Say
To build an effective commercialization strategy, device manufacturers must look past the anecdotes of denied claims and examine the systemic data published by CMS, the HHS Office of Inspector General (OIG), and independent research organizations like the Kaiser Family Foundation.
According to KFF's analysis of CMS prior authorization data:
- Overall Denials: In 2024, Medicare Advantage plans processed approximately 53 million prior authorization requests. Of these, plans issued full or partial denials for 4.1 million requests, resulting in an average denial rate of 7.7%.
- The Appeals Loophole: Only 11.5% of denied prior authorization requests were ever appealed by providers or enrollees. The remaining 88.5% of denials were accepted as final, meaning the patient did not receive the service or the provider absorbed the cost.
- The Overturn Rate: For the small fraction of denials that were appealed, the results were overwhelming: 80.7% of appeals resulted in the plan overturning its initial denial, either fully or partially.
Medicare Advantage Prior Authorization Funnel, 2024
Rates from KFF; absolute appeal counts are MedDeviceGuide
calculations applied to the KFF rates (KFF does not publish them).
+---------------------------------------------------------------+
| Determinations: 52.8 Million [KFF] |
+--------------------+------------------------------------------+
| Fully favorable: 48.7 Million (>90%) [KFF] |
+--------------------+------------------------------------------+
| Denials issued: 4.1 Million (7.7%) [KFF] |
| ~73% denied in full [KFF] |
+--------------------+------------------------------------------+
| Appeals filed: ~471,000 (11.5% of denials) [computed] |
+--------------------+------------------------------------------+
| Appeals overturned:~380,000 (80.7% of appeals) [computed] |
+--------------------+------------------------------------------+
| Denials never ~3.63 Million (88.5%) [computed] |
| appealed: |
+---------------------------------------------------------------+
The bottom row is the number device commercialization teams should carry around. Roughly 3.6 million denied requests a year go unchallenged — and given the 80.7% overturn rate on the ones that are challenged, a large share of those were very likely approvable. That gap is not a coverage problem or an evidence problem. It is an administrative-friction problem, and it is the single place where a manufacturer's reimbursement support program produces the most measurable return.
This data reveals a critical operational reality: initial prior authorization denials are frequently incorrect, and the vast majority of appeals are successful. For a device manufacturer, this means that having a denial is not a dead end—it is the beginning of an operational workflow. The major failure point is the lack of provider action: 88.5% of denials are never appealed due to the administrative burden of filing the appeal.
The HHS OIG Audits on Post-Acute Denials
The aggregate 7.7% denial rate conceals enormous variation by setting, and the two HHS Office of Inspector General reports published June 8, 2026 — OEI-09-24-00330 (LTCH and IRF) and OEI-09-24-00331 (SNF) — are the sharpest evidence available on where devices actually get blocked. Both analyze June 2024 data from 19 MAOs covering 29.3 million enrollees, or 86% of total Medicare Advantage enrollment at the time.
The setting-level denial rates are the finding that should reset device teams' assumptions:
MA Prior Authorization Denial Rates by Post-Acute Setting (OIG, June 2024)
+---------------------------+-------------+---------------+------------------+
| Setting | Requests | Denial Rate | Overturned on |
| | | | appeal |
+---------------------------+-------------+---------------+------------------+
| Long-Term Care Hospital | ~3,200 | 65% (~2,100) | 36% |
| Inpatient Rehab Facility | ~19,400 | 54% (~10,500)| 43% |
| Skilled Nursing Facility | ~109,400 | 12% (~13,500)| 95% |
| All MA services (KFF, CY24)| 52.8M | 7.7% | 80.7% |
+---------------------------+-------------+---------------+------------------+
- Denial rates 7–8x the program average. MAOs denied roughly two-thirds of LTCH admission requests and more than half of IRF requests. For manufacturers of ventilators, specialty beds, rehabilitation technology, wound-care systems, and any device whose utilization depends on the patient reaching a post-acute bed, the binding constraint is not your device's coverage status — it is whether the site of care gets authorized at all.
- The SNF appeal signal is extraordinary. SNF denials were appealed 18% of the time, and MAOs overturned 95% of those appeals. OIG's own framing is that an overturn rate this high raises the question of whether the initial denials were appropriate at all. LTCH denials were appealed 36% of the time and IRF denials 31%, with 36% and 43% overturn rates respectively.
- Plan choice dominates clinical need. SNF denial rates across the 19 MAOs ranged from 0.4% to 23% — a nearly 60-fold spread. Whether a patient gets a device-dependent post-acute stay depends substantially on which plan they enrolled in, not on their clinical presentation.
- Concentration in the three largest plans. OIG found the three largest MAOs by enrollment — UnitedHealth Group, Humana, and CVS Health — denied LTCH and IRF requests at some of the highest rates among their peers while receiving the majority of requests. Territory-level access can therefore swing sharply on local MA market share.
A note on reading these figures: the OIG denial rates are computed on requests, not on patients or claims, and reflect a single month. They are not incidence rates for the underlying clinical need, and they should not be added to or compared directly against the KFF annual figures, which cover all services across the full year.
5. Internal Coverage Criteria, Transparency, and Clinical Pathways
One of the most contentious issues in Medicare Advantage is the use of "internal coverage criteria." When CMS has not issued a national coverage policy (NCD) and the local MAC has no local policy (LCD) for a specific medical device, MA plans develop their own internal guidelines to determine medical necessity. Historically, many plans kept these internal guidelines proprietary, making it difficult for device manufacturers to know exactly what clinical evidence, endpoints, or patient indications were required to secure approval.
What Is Already In Force vs. What the CY2026 Rule Deferred
CMS has been tightening the rules around internal coverage criteria across multiple rulemaking cycles, and device teams must understand exactly what is — and is not — yet required:
- Alignment with Traditional Medicare (in force): Under 42 CFR § 422.101, MA plans may not use internal criteria to deny coverage for an item or service that meets traditional Medicare coverage rules. Where an NCD or LCD establishes specific coverage criteria for a device (such as spinal cord stimulation), the plan's medical-necessity review must apply those Medicare coverage criteria; internal criteria can only supplement, not override, them. The CY2024 MA Final Rule (CMS-4201-F) reinforced that utilization-management criteria must be based on current evidence.
- What the CY2026 Final Rule DID finalize — the approved-admission hold: The Contract Year 2026 Policy and Technical Changes Final Rule (CMS-4208-F, issued April 4, 2025; published April 15, 2025 at 90 FR 15792) finalized several enrollee protections. Most relevant to device teams is the restriction on reopening an approved authorization. The operative provision is 42 CFR § 422.138(c): if the MA organization approved an item or service through prior authorization, a pre-service determination, or a concurrent determination made during the enrollee's receipt of inpatient or outpatient services, it may not later deny coverage on the basis of lack of medical necessity, and may not reopen that decision for any reason except good cause (§ 405.986 and § 422.616) or reliable evidence of fraud or similar fault. The CY2026 rule tightened this specifically for inpatient admissions, so that a plan cannot reopen an approved admission on the strength of clinical information gathered after the approval — leaving obvious error and fraud as the only routes. The rule also closed appeals loopholes by clarifying that concurrent and ongoing-care coverage decisions are appealable organization determinations, and by requiring plans to notify the requesting provider, not just the enrollee.
- What the CY2026 Final Rule DEFERRED — transparency and the definition of "internal coverage criteria": The proposed CY2026 rule would have (a) formally defined "internal coverage criteria," (b) required plans to publicly post their internal coverage criteria on their websites, and (c) added an enhanced health-equity analysis of utilization-management policies. CMS did not finalize these transparency provisions — it deferred them for future rulemaking, despite receiving more than 33,000 public comments. The practical consequence: there is not yet a blanket federal requirement that MA plans publish their internal coverage criteria, so manufacturers should not assume every plan's rules are publicly downloadable today. Until CMS finalizes these provisions, the most reliable way to obtain a plan's criteria is to request them directly from the plan's medical director or utilization-management department.
Regardless of whether a plan publishes its criteria, under 42 CFR § 422.566(d) any partially or fully adverse medical-necessity decision on a prior authorization request must be reviewed by a physician or other appropriate health care professional with expertise relevant to the services at issue (including knowledge of Medicare coverage criteria) before the plan issues the decision. This requirement prevents plans from relying on non-clinical administrative staff or generalist reviewers to deny complex medical device technologies.
6. A Device-Maker's Playbook: Coding, Evidence, Payer Engagement, and Appeal Readiness
To survive in a Medicare Advantage-dominated market, medical device manufacturers must transition from a reactive "billing support" model to a proactive, operationally integrated market access strategy. This sits downstream of two prerequisites covered elsewhere on MedDeviceGuide: correct code assignment, addressed in our CPT, HCPCS, and ICD coding strategy guide, and the broader payment architecture set out in our complete medical device reimbursement guide. Prior authorization strategy fails without both.
Medical Device MA Prior Authorization Playbook
|
+--------------------------------+--------------------------------+
| | |
Payer Engagement Workflow Integration Appeal Readiness
- Audit internal criteria - Standardize documentation - Pre-package letters
- Supply clinical dossiers - Embed EHR clinical templates - Establish appeal hubs
- Monitor peer review - Leverage FHIR ePA APIs - Track denial metrics
Step 1: Map the Payer Criteria Landscape
Do not guess how UnitedHealthcare, Humana, or Aetna evaluate your device. Where a plan voluntarily publishes its internal coverage guidelines (a growing number do), download them; otherwise request them directly from the plan's medical director. Keep in mind that CMS's proposed CY2026 requirement to mandate public posting of internal coverage criteria was deferred and is not yet in force, so proactive outreach remains essential.
- Identify the exact patient indications, diagnostic thresholds, prior conservative therapy failures (e.g., "must fail 6 weeks of physical therapy"), and contraindications they require.
- Compare these criteria against your FDA-approved labeling and the clinical trial data in your dossier.
- If a plan's criteria are outdated or more restrictive than the corresponding Local Coverage Determination (LCD), submit a formal request for policy revision, invoking the Medicare coverage-rule alignment standard at 42 CFR § 422.101 (internal criteria may not override NCD/LCD coverage).
- Where your evidence base is still maturing, note that MA plans do not operate a coverage-with-evidence mechanism of their own; understanding how Medicare coverage with evidence development works in traditional Medicare helps you frame what a plan will and will not accept as an interim evidentiary position. For established products, an outcomes-based or value-based contract is often a faster route to criteria change than a policy-revision request alone.
Step 2: Build EHR-Ready Documentation Templates
Prior authorization denials are most commonly triggered by "lack of documentation"—meaning the provider failed to send the specific clinical note that proves the patient met the plan's criteria.
- Develop clear, standardized templates and clinical checklists that physicians can use within their EHR systems when evaluating candidates for your device.
- Ensure these templates prompt the physician to document the exact clinical criteria required by the major MA plans (e.g., specific diagnostic scores, duration of symptoms, and history of conservative treatment).
- Align these templates with the emerging FHIR Prior Authorization API standards to prepare for electronic prior authorization (ePA).
Step 3: Establish a Dedicated Reimbursement Hotline and Appeal Support Program
Because providers only appeal 11.5% of prior authorization denials, manufacturers must actively reduce the administrative barrier to appealing.
- Provide pre-packaged appeal templates that contain the specific scientific arguments, clinical citations, and regulatory guidelines necessary to challenge a denial.
- Under 42 CFR § 422.566, highlight that any adverse decision must be reviewed by a physician with relevant expertise—include a request in your appeal template for the CV and credentials of the plan’s reviewing clinician.
- Deploy a dedicated reimbursement support team (reimbursement hotline) that can walk provider billing staff through the appeal steps, track outstanding denials, and monitor the 7-day standard timeline.
Step 4: Leverage the 2026 Timelines and Denial Transparency
Train your sales and billing teams on the January 2026 rules:
- Monitor plan response times. If an MA plan fails to issue a decision on a standard request within 7 calendar days, use the delay to escalate the request with the plan's provider relations representative.
- Analyze the required detailed denial reasons. If a plan issues a denial, immediately audit the specific cited reason. If the plan failed to provide a specific clinical reason, challenge the denial on procedural grounds under 42 CFR § 422.122.
7. How MA Prior Authorization Compares to Traditional Medicare
While Medicare Advantage plans use prior authorization as a proactive utilization management gate, traditional fee-for-service (FFS) Medicare relies on a fundamentally different model. For device manufacturers, navigating the two systems requires distinct operational approaches.
Comparison of Prior Authorization and Coverage Gateways (as of July 2026)
+--------------------------+----------------------------+----------------------------+
| Feature | Traditional Medicare (FFS) | Medicare Advantage (Part C)|
+--------------------------+----------------------------+----------------------------+
| Primary Coverage Gate | Retrospective Audits / LCD | Prospective Prior Auth |
| Scope of PA | 74 DMEPOS codes + OPD list | Any service the plan lists |
| Standard PA Timeline | 5 business days, max 7 | 7 calendar days |
| | calendar days (DMEPOS, | (CMS-0057-F, from |
| | from Jan 1, 2025) | Jan 1, 2026) |
| Expedited PA Timeline | 2 business days (DMEPOS) | 72 hours |
| Clinical Coverage Source | NCD / LCD / MAC Guidance | NCD/LCD + Internal Criteria|
| Electronic PA (ePA) API | Optional / Pilot | Mandated by Jan 1, 2027 |
| Level 2 Appeal Reviewer | QIC — Maximus (DME and | Part C IRE — C2C |
| | Part A West); C2C (Part A | Innovative Solutions |
| | East, Part B North/South) | (since May 1, 2026) |
+--------------------------+----------------------------+----------------------------+
A. The DMEPOS Prior Authorization Program
Traditional Medicare does operate a prospective prior authorization program, but it is strictly limited to items on the DMEPOS Required Prior Authorization List. This list (which we detail in our companion article on DMEPOS Prior Authorization) is managed by CMS and applies uniformly across all jurisdictions. If an item is on the list, a supplier must obtain a "provisional affirmation" from the DME MAC before delivering the device.
In contrast, Medicare Advantage plans can require prior authorization for any DMEPOS item, regardless of whether it is on the CMS FFS list. MA plans also set their own documentation requirements and timelines, creating a highly fragmented market for suppliers who must navigate hundreds of different commercial plan policies.
B. Outpatient Department (OPD) Prior Authorization
Traditional Medicare also requires prior authorization for certain services performed in Hospital Outpatient Departments (OPD), such as blepharoplasty, rhinoplasty, vein ablation, and cervical fusion. The OPD program is focused on clinical settings, whereas MA prior authorization is focused on managing the overall cost and necessity of the procedure itself, regardless of where it is performed.
C. The Appeal Process and Independent Review
In traditional Medicare, if a claim is denied, the provider has access to a structured, independent five-level appeal process. The second level is handled by a Qualified Independent Contractor (QIC) entirely independent of the MAC that issued the denial. For DMEPOS specifically, that QIC is Maximus, Inc.
In Medicare Advantage, the initial appeal (reconsideration) is handled internally by the MA plan itself. If the plan upholds its denial, federal rules require the plan to automatically forward the case to the Medicare Advantage Independent Review Entity (IRE). Check your appeal templates here: CMS transitioned the Part C IRE contract in 2026. MAXIMUS Federal Services processed Part C reconsideration requests received through April 30, 2026; effective May 1, 2026, C2C Innovative Solutions, Inc. is the Part C IRE. Manufacturer-supplied appeal packets, provider training decks, and reimbursement-hotline scripts written before mid-2026 routinely name the wrong entity and the wrong Jacksonville filing addresses — a small error that delays an already slow process.
The automatic forwarding is a crucial protection for enrollees: if the plan refuses to overturn its denial on the first appeal, an independent third party reviews the clinical records. Device manufacturers must ensure the provider's initial appeal package is fully optimized, because that same record is what the IRE will evaluate.
D. The WISeR Model: Prior Authorization Arrives in Traditional Medicare
A 2026 development narrows the traditional-versus-MA contrast. The CMS Innovation Center's Wasteful and Inappropriate Service Reduction (WISeR) Model began on January 1, 2026 and runs for six performance years through December 31, 2031 in six states: New Jersey, Ohio, Oklahoma, Texas, Arizona, and Washington. Participants and MACs began accepting requests on January 5, 2026 for services furnished on or after January 15, 2026. WISeR pairs each state with a technology-enabled review entity working alongside the MAC — Genzeon (NJ), Innovaccer (OH), Humata Health (OK), Cohere Health (TX), Zyter (AZ), and Virtix Health (WA) — using AI and machine learning with human clinical review, under an arrangement that shares savings from avoided spending with the participant.
The service list is where this becomes a device story rather than a policy story. WISeR's selected services are concentrated in exactly the categories where implantable and procedural device revenue sits: electrical nerve stimulator implants including deep brain stimulation and vagus nerve stimulation, epidural steroid injections, facet joint interventions, cervical fusion, and skin substitutes. A neuromodulation or spine manufacturer with meaningful volume in Texas or Arizona now faces prior authorization on traditional Medicare patients for the first time.
Three points matter for planning. First, WISeR is geographically and procedurally limited — a defined service list in six states, with the model generally applying based on where the service is furnished rather than where the patient lives or where billing is done. It is not a nationwide FFS prior authorization mandate, and it does not apply to Medicare Advantage. Second, submission is a choice, not an exemption: a provider either submits a pre-service request or furnishes the service and accepts pre-payment medical review of the claim. There is no path that avoids review. Third, the recovery math differs sharply by program. MA prior-authorization denials are overturned on appeal roughly 80% of the time, whereas traditional Medicare FFS appeal overturn rates have historically run far lower — so an identical clinical scenario denied under WISeR is generally harder to recover than under an MA plan. Because CMS can revise the selected-service list in future performance years, manufacturers whose procedures sit adjacent to the current list should monitor the WISeR service schedule as an early warning that the FFS-versus-MA prior authorization divide is closing.
8. Frequently Asked Questions
Does Medicare Advantage have to cover a device that traditional Medicare covers?
Yes. Medicare Advantage plans are legally required to cover all services and devices that are covered under traditional Medicare Part A and Part B. If a device has national coverage under an NCD or local coverage under an LCD, the MA plan must cover it. However, the plan can require prior authorization to verify that the patient meets the specific clinical criteria of that NCD or LCD.
How long does a Medicare Advantage plan have to decide a prior authorization request after the January 2026 rule change?
Beginning January 1, 2026, under the CMS Interoperability and Prior Authorization Final Rule (CMS-0057-F), Medicare Advantage plans must make prior authorization decisions within 7 calendar days for standard requests and within 72 hours for expedited requests. This is a significant reduction from the prior 14-day standard.
If an MA plan denies prior authorization, how often do appeals work?
According to CMS data analyzed by the Kaiser Family Foundation, appeals are highly successful. In 2024, 80.7% of all prior authorization appeals resulted in the Medicare Advantage plan overturning its initial denial. Despite this high success rate, providers and enrollees only appealed 11.5% of all denials, primarily due to the administrative burden of filing the appeal.
What are internal coverage criteria in Medicare Advantage and can a manufacturer influence them?
Internal coverage criteria are clinical guidelines developed by an MA plan to determine the medical necessity of a device or service when no national (NCD) or local (LCD) Medicare policy exists. Under existing rules (42 CFR § 422.101 and the CY2024 MA Final Rule), these criteria must be evidence-based and may not be used to deny care that meets traditional Medicare coverage rules. The proposed CY2026 MA Final Rule would have gone further by formally defining "internal coverage criteria" and requiring plans to publish them on their websites, but CMS deferred those transparency provisions for future rulemaking rather than finalizing them — so public posting is not yet a blanket federal requirement. Manufacturers can still influence these criteria by requesting them from plans' medical directors and submitting clinical dossiers that demonstrate the device meets the evidentiary standards of the rule.
Does prior authorization apply to DME/prosthetics/mobility devices differently in MA than traditional Medicare?
Yes. In traditional Medicare, prior authorization is only required for a specific subset of codes on the CMS DMEPOS Required Prior Authorization List. In Medicare Advantage, plans have the authority to require prior authorization for any durable medical equipment, prosthetic, orthotic, or supply code. The documentation requirements, coding edits, and clinical pathways can vary significantly from plan to plan, unlike traditional Medicare's uniform standards.